An interventional study of PRISM in Post-Traumatic Stress Disorder (PTSD), sponsored by GrayMatters Health Ltd.. Completed at 5 sites in 2 countries. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-06-01.
Sponsored by GrayMatters Health Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Stress Disorders, Post-Traumatic with a site in Israel — 24 open to participants now, 25 under way, 1 of them phase 3. Stress Disorders, Post-Traumatic · Israel.
Among the 103 studies in Stress Disorders, Post-Traumatic with a site in Israel, this one is the 30th largest by enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2020, is one of 54 with no phase, and was the 69th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →24 of the 103 studies in Stress Disorders, Post-Traumatic with a site in Israel are open now. Recruiting first, the newest first:
University of Haifa · Sites in Israel
Ages 18–70
Barzilai Medical Center · Sites in Israel
Ages 18–120
Community Stress Prevention Center · Sites in Israel
Ages 18+
Community Stress Prevention Center · Sites in Israel
Ages 18+
Tel Aviv University · Sites in Israel
Ages 18–70
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 22 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 5 · Phase 4 3
First in 2003; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 60 across the 77 interventional studies, 110 across the 24 observational. Of the 52 that completed or were terminated, 7 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 103 have an industry lead sponsor. The 10 most frequent:
GrayMatters Health Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
GrayMatters Health Ltd. has 2 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
4 of the studies in Stress Disorders, Post-Traumatic with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07737054Tel-Aviv Sourasky Medical CenterTrauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD | 2026-12-01 |
| NCT05732155Guy SchusheimPreliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD | 2027-06-01 |
| NCT07473362Medical Corps, Israel Defense ForceHyperbaric Oxygen Therapy for Post Traumatic Stress Disorder - a Pragmatic, Double Blinded Randomized Trial | 2027-08-31 |
| NCT06639061Tel Aviv UniversityNeuromodulation of the Hippocampus to Reduce Intrusive Re-Experiencing in PTSD: A Randomized Controlled Trial | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 103 studies in Stress Disorders, Post-Traumatic with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Prospective, Single-Arm, Open-Label Pilot Trial, to Assess Safety and Effectiveness of Process-Instructed Self neuro-Modulation ("Prism"), as an Adjunct to Standard of Care, in Subjects with Post-Traumatic Stress Disorder (PTSD)
Prism is a software device intended for neurofeedback (NF) training (i.e. operant condition based on EEG signals, also known as EEG-biofeedback), to be used in combination with a standard computer and supported EEG hardware. For purposes of this training, information for feedback is derived and processed from several EEG channels. Prism provides visual and/or auditory signals that correspond to the patient's computed EEG signal, which serves as a surrogate indicator of achieving a state of reduced amygdala activity.
The study is a Prospective, Single-Arm, Open-Label Pilot Trial, to Assess Safety and Effectiveness of Process-Instructed Self neuro-Modulation ("Prism"), as an Adjunct to Standard of Care, in Subjects with Post-Traumatic Stress Disorder (PTSD).
The study population will include subjects diagnosed with Post-Traumatic Stress Disorder (PTSD) from 1 year to 20 years after index trauma. The total expected enrollment is up to 100 subjects in one or more sites.
The study's primary objective is to assess the safety and effectiveness of fifteen (15) EEG-NF training sessions using the Prism software in reducing PTSD-related symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects diagnosed with PTSD will be recruited from the community and from local clinical programs. All subjects will undergo Prism neurofeedback training.
Device: PRISM
Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.
Clinician Administered PTSD Scale (CAPS - 5)
The primary objective of this study is to assess the proportion of subjects who demonstrate clinically meaningful improvement in the Clinician Administered PTSD Scale (CAPS - 5) score from Baseline to the 3 months follow-up visit. Clinically meaningful improvement is defined here as a 6-point reduction or more in the CAPS-5 score.
Time frame: Baseline visit (Week 1) and 3 month Follow-up visit
PCL-5 response rate
To assess the proportion of subjects who demonstrate clinically meaningful improvement in the PTSD Checklist for DSM-5 (PCL-5). Clinically meaningful improvement is defined here as a 10-point reduction or more in the PCL-5 score
Time frame: Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit
ERQ score
Change from baseline to Month 3 visit in ERQ score
Time frame: Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit
PHQ-9 score
Change from baseline to Month 3 visit in PHQ-9 score
Time frame: Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit
Clinical Global Impression (CGI)
Change from baseline to Month 3 visit in CGI score
Time frame: Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit
Abbreviated PCL (APCL)
To assess the change in the score of the abbreviated PCL scale (APCL, assessed weekly during the EFP-NF training period)
Time frame: through study completion, an average of 8 weeks
learning success of the EFP-based neurofeedback
To quantify the learning success of the EFP-based neurofeedback (namely: learning volitional down-regulation of the Amyg-EFP signal, over time, during the EFP-NF training period)
Time frame: through study completion, an average of 8 weeks
Patient satisfaction survey
To quantify patient satisfaction from the EFP-NF training using survey
Time frame: through study completion, an average of 5 month
Remission rate
To assess the Remission rate at post training visit (8-9 weeks) and at the 3 months follow-up visit
Time frame: Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2020 to primary completion in May 2022, 18 months.
Of 1,094 interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →
GrayMatters Health Ltd.